A GLYCO HUMANIZED ANTIBODY PLATFORM WITH EMBEDDED
TECHNOLOGY THAT RENOVATES IMMUNOLOGICAL TREATMENTS

Innovative immunotherapy

XENOTHERA is addressing unmet medical needs with proprietary Glyco-Humanized Antibodies:

Genetic engineering of the bio-production species
Immunogen strategy and optimization
Enhanced therapeutic efficiency of GH-pAb mix
Pharmaceutical development done and stability data for more than 2 years
Translational development program experience

Therapeutic domains:

Immunology
Multi-Drug Resistant Bacteria
Oncology
Viral infections
Others

TEAM

Odile Duvaux

Chief Executive Officer

M.D., Ph. D., formerly main partner in a consultant firm specialized in strategy DMJ Consultants

More

Bernard Vanhove

Chief Operating Officer

Ph. D., immunilogist, formerly Research Director at CNRS and INSERM, co-founder and ex-COO of Effimune

More

Didier Coquoz

Clinical & Regulatory Affairs

PhD in clinical pharmacology, Chief Development and Regulatory Officer for biotech/small pharmas

More

Alexandre Lemoalle

Business Development

Former M&A VP for Sanofi, had many finance experiences in the pharmaceutical industry

More

Elsa Lheriteau

Project Manager

Ph. D. in Gene Therapy, Molecular Biology and Vectorology, University of Nantes, France

More

Pierre-Joseph Royer

Research Engineer

Ph. D. in Immunology, University of Nantes, France

More

Carine Ciron

Research Engineer

Ph. D. in Gene Therapy, Molecular Biology and Vectorology, University of Nantes, France

More

Gwenaelle Evanno

Research

Masters in Biochemistry, University of Rennes, France

More

Juliette Rousse

Research

Masters from University of Nantes, France, completing her Ph. D. with Xenothera

More

Sophie Despons

Administration & Finance

External Contractor
Scientific advisor

Jean-Paul Soulillou

Emeritus Professor of Medicine, worldwide renowned immunologist. 2016 winner of the Medawar Prize

More
External Contractor
Scientific advisor

Emanuele Cozzi

Chairman of the Scientific Advisory Board

MD, Professor of Immunology at the University of Padua, former chairman of the International Xenotransplantation Association

More
External Contractor
Scientific advisor

Jean-Marie Bach

D.M.V., Ph.D., Professor at Oniris, Veterinary school of Nantes

More
External Contractor
Scientific advisor

Sophie Brouard

D.M.V., Ph.D., leads a team of 32 researchers at ITUN, specialist in immunology and transplantation

More
External Contractor
Genetic Engineering

Cesare Galli

D.M.V., Ph.D., founder of the company Avantea (Cremona, Italy), worldwide renowned animal genetic engineer

More
External Contractor
Development & Market Access

Marc Bouillet

M.D., former partner/CEO in several pharmaceutical companies and patient associations

More

An agile company with a fast-paced development

XENOTHERA is a clinical stage biotech at the top of innovation, which creates new therapeutic modes in numerous domains. Our patented technological platform is built on a double expertise of immunology and genetic engineering. It develops innovative  approaches in immunotherapy by marketing Glyco-Humanized Polyclonal Antibodies (GH-pAb). Our antibodies are engineered to display high therapeutic properties. XENOTHERA’s platform ensures short-time development thanks to our mastery of the entire process, from animal genetics, choice of the immunogen, selection and purification of antibodies, and access to market authorization in accelerated timescale. Within less than 5 years, XENOTHERA has brought to clinic its first product LIS1, a novel induction treatment in Solid Organ Transplantation, addressing a $1Bn market. It has also established in vivo Proof-of-Concept in Immuno-Oncology and Multi-Drug Resistant infections.

Pipeline

Products in development

Latest News

Xenothera receives approval for first in man Kidney Transplant Clinical Trial

Nantes, September 11th, 2019 – Xenothera announces it has received  Czech Republic regulatory agency approval to begin its Phase I/II clinical trial of its LIS1 product developed as induction treatment in solid organ[…]

Read more

Xenothera presents at ESOT 2019

XENOTHERA will participate at ESOT 2019 that will take place in Copenhagen in Sept.19.During the congress the preclinical data obtained with the first product, LIS1, for prevention of graft rejection,[…]

Read more

Xenothera announces receivability of its Clinical Trial Application at the Czech Republic regulatory agency for a first in man clinical trial of LIS1 in kidney transplanted patients with dose escalation.

Nantes, June 21st, 2019 – Xenothera announces receivability after its submission of a Clinical Trial Application (CTA) with Czech Republic regulatory agency for a Phase I/II trial of its LIS1 product developed as induction[…]

Read more

Xenothera is built on a worldwide network of scientific & medical collaboration

Related scientific papers

Next-generation Porcine Low Immunogenicity Anti-Lymphocyte Immunoglobulins shows selective depletion of T lymphocytes versus Treg and Breg

Rousse et al, ESOT 2019,  Copenhagen, Denmark

LINK

Anti-Neu5Gc responses in kidney allograft recipients after treatment with Rabbit Anti-Thymocyte Globulins.

Rousse et al, ESOT 2019, Copenhaguen, Denmark

LINK

Next-generation Porcine Low Immunogenicity Anti-Lymphocyte
immunoglobulins efficiently delay skin graft rejection in non-human primate

Ciron et al, ESOT 2019,  Copenhagen, Denmark

LINK

Quantitative and qualitative changes in anti-Neu5Gc antibody response following rabbit anti-thymocyte IgG induction in kidney allograft recipients

Rousse et al, Eur J Clin Invest. 2019. Apr;49 (4)

LINK

Anti-Gal and anti-Neu5GC responses in non-immunosuppressed patients following treatment with Anti-Thymocyte Globulin

Salama et al, 2017

LINK

Neu5Gc and α1-3 GAL Xenoantigen Knockout Does Not Affect Glycemia Homeostasis and Insulin Secretion in Pigs

Salama et al, 2017

LINK

Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs

Reynard et al, PLoS One. 2016

LINK

Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival

Couvrat-Desvergnes et al, J Clin Invest. 2015

LINK

Potential deleterious role of anti-Neu5Gc antibodies in xenotransplantation.

Salama et al, Xenotransplantation. 2015

LINK

Long-term IgG response to porcine Neu5Gc-antigens without transmission of PERV in burn patients treated with porcine skin xenografts

Scobie et al, J Immunol. 2013

LINK

To contact us, use the form or see our full contact below

Xenothera
1 rue Vauban – 44000 Nantes – France

Xenothera is a start-up in biotechnology, specialized in immunology, infectious diseases and oncology

Investors already trusted us in 2014, 2016 and 2018 by funding the company for 6M€. XENOTHERA is currently preparing its series B fundraising in order to finance LIS1 pivotal trial and to bring two other products to clinic (XAB05 in MDR infections, XON03 in oncology ). Our products will offer a substantial patient benefit and aim to solve major public health issues.

a